SARS-CoV-2 has spread exponentially to nearly every nation in the world, and healthcare workers are continuously striving for accessible drugs that might possibly treat affected individuals, most importantly which include RdRp inhibitors.

The widespread existence of many viruses is largely due to their rapidly mutating genomes of ribonucleic acid (RNA), which cause the infection to continue despite host cell challenges. RNA-dependent RNA polymerase (RdRp) occurs within the RNA genome of viruses, and is a highly flexible enzyme that assists in RNA synthesis by catalyzing the phosphodiester bond-dependent RNA-template formation.

During the RNA synthesis process, lack of exonuclease activity causes RdRps to have a high rate of copying error which is calculated to be about 10^-4. While mutations are commonly regarded as harmful to host cells, the RNA virus progeny population benefits from increased mutation rates. The mutants can survive under various environmental factors as the mutation of these viruses was caused under extreme pressure by the host organism’s defense physiology.

Human coronaviruses are made up of various non-structural proteins like the proteases nsp3 and nsp5, as well as RdRp. Inhibitors of RdRp have also been studied and shown remarkable performance in the reduction of SARS-CoV-2.

Diagnostic Pathology: Open Access is collecting manuscripts all over the globe on COVID-19 to provide a platform for the Health-care professionals and distinguished Researchers around the world to discuss the analysis, strategies and potential therapies in combating COVID-19 and foster discussion in all the relevant aspects of Pathology such as Immunopathology, Virtual Pathology, Tissue based Diagnosis, Immunohistochemistry, Diagnostic Pathology of Infectious Diseases.

We have also announced a Special Issue on “Therapeutic Applications in COVID-19” acknowledging the significance in the Global Scientific Community. The Special Issue is being edited by our honourable Executive Editorial Chair Person Dr. Maria Teresa Mascellino. The Submissions are Open!

Regards,

Matthew Richard
Diagnostic Pathology: Open Access
WhatsApp: +32-2-808-66-57
E-mail id: diagnospathol@pathologyinsights.org